Skip to main content
×
×
Home

Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study

  • C. CONDE-GLEZ (a1), E. LAZCANO-PONCE (a1), R. ROJAS (a1), R. DeANTONIO (a2), L. ROMANO-MAZZOTTI (a3), Y. CERVANTES (a3) and E. ORTEGA-BARRÍA (a4)...
Summary

Serum samples collected during the National Health and Nutrition survey (ENSANUT 2006) were obtained from subjects aged 1–95 years (January–October 2010) and analysed to assess the seroprevalence of Bordetella pertussis (BP) in Mexico. Subjects' gender, age, geographical region and socioeconomic status were extracted from the survey and compiled into a subset database. A total of 3344 subjects (median age 29 years, range 1–95 years) were included in the analysis. Overall, BP seroprevalence was 47·4%. BP seroprevalence was significantly higher in males (53·4%, P = 0·0007) and highest in children (59·3%) decreasing with advancing age (P = 0·0008). BP seroprevalence was not significantly different between regions (P = 0·1918) and between subjects of socioeconomic status (P = 0·0808). Women, adolescents and young adults were identified as potential sources of infection to infants. Booster vaccination for adolescents and primary contacts (including mothers) for newborns and infants may provide an important public health intervention to reduce the disease burden.

Copyright
Corresponding author
* Author for correspondence: Dr C. Conde-Glez, Instituto Nacional de Salud Pública, Avenida Universidad 655, Colonia Santa María Ahuacatitlán, 62508 Cuernavaca, Morelos, México. (Email: cjconde@insp.mx)
References
Hide All
1. Guiso, N, Liese, J, Plotkin, S. The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14–15, 2010. Human Vaccines 2011; 7: 481488.
2. Ulloa-Gutierrez, R, Carvajal-Riggioni, D, Baltodano, A. Pertussis: should we improve intensive care management or vaccination strategies? Expert Review of Vaccines 2011; 10: 4953.
3. WHO. Pertussis vaccines: WHO position paper. Weekly Epidemiological Record 2010; 85: 385400.
4. Black, RE, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 19691987.
5. WHO. Immunization profile (http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm?C=mex). Accessed 10 February 2012.
6. Ulloa-Gutierrez, R, Avila-Aguero, ML. Pertussis in Latin America: current situation and future vaccination challenges. Expert Review of Vaccines 2008; 7: 15691580.
7. Santos, JI. El programa nacional de vacunacion: orgulla de Mexico (http://www.ejournal.unam.mx/rfm/no45-3/RFM45308.pdf). Accessed 8 February 2012.
8. Ulloa-Gutierrez, R, et al. The Global Pertussis Initiative: meeting report from the regional Latin America meeting, Costa Rica, 5–6 December, 2008. Human Vaccines 2010; 6: 876880.
9. Tan, T, Trindade, E, Skowronski, D. Epidemiology of pertussis. Pediatric Infectious Disease Journal 2005; 24: S10S18.
10. Guiso, N, et al. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11–12 January 2010. Vaccine 2011; 29: 11151121.
11. Rendi-Wagner, P, et al. The seroepidemiology of Bordetella pertussis in Israel – estimate of incidence of infection. Vaccine 2010; 28: 32853290.
12. Heininger, U, Cherry, JD. Pertussis immunization in adolescents and adults – Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opinion on Biological Therapy 2006; 6: 685697.
13. Expert group on vaccinations for pertussis. Consensus on the clinical and microbiologic diagnosis of Bordetella pertussis and infection prevention. Salud Publica de Mexico 2011; 53: 5765.
14. Olaiz-Fernández, G, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2006. (http://www.insp.mx/ensanut/ensanut2006.pdf). Accessed 2 April 2013.
15. Riffelmann, M, et al. Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis . Journal of Clinical Microbiology 2010; 48: 44594463.
16. Inandi, T, Guraksin, A, Hacialioglu, N. Seroprevalence of pertussis among children in Eastern Turkey. Public Health 2005; 119: 550555.
17. Chiu, TF, et al. Pertussis seroepidemiology in Taipei. Journal of the Formosan Medical Association 2000; 99: 224228.
18. Giammanco, A, et al. Seroepidemiology of pertussis in Italy. Reviews of Infectious Diseases 1991; 13: 12161220.
19. National Institute of Statistics, Geography and Informatics. Population and Household Census. Mexico, 2010. Census sample. Database. (http://www.censo2010.org.mx/). Accessed 2 April 2013.
20. Halperin, BA, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clinical Infectious Diseases 2011; 53: 885892.
21. Esen, B, et al. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. Journal of Clinical Laboratory Analysis 2007; 21: 154161.
22. WHO. The immunological basis for immunization series: module 4: pertussis – update 2009 (http://whqlibdoc.who.int/publications/2010/9789241599337_eng.pdf). Accessed 10 February 2012.
23. Libster, M, Edwards, KM. Re-emergence of pertussis: what are the solutions? Expert Review of Vaccines 2012; 11: 13311346.
24. Guerrero, ML, et al. Pertussis in adolescents in Mexico City: a prospective cohort study. Presented at the 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), Melbourne, Australia, 16–19 November 2011 (http://www.kenes.com/wspid2011/abstracts/pdf/235.pdf). Accessed 16 March 2012.
25. Cattaneo, LA, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons aged 1–65 years. Journal of Infectious Diseases 1996; 173: 12561259.
26. De Melker, HE, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis . Journal of Clinical Microbiology 2000; 38: 800806.
27. De Melker, HE, et al. The incidence of Bordetella pertussis infection estimated in the population from a combination of serological surveys. Journal of Infection 2006; 53: 106113.
28. Olin, P, et al. Randomized controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the study of pertussis vaccines. Lancet 1997; 350: 15691577.
29. De Greef, SC, et al. Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis . PLoS ONE 2010; 5: e14183.
30. Pebody, RG, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and Infection 2005; 133: 159171.
31. Brooks, DA, Clover, R. Pertussis infection in the United States: role for vaccination of adolescents and adults. Journal of the American Board of Family Medicine 2006; 19: 603611.
32. Hallander, HO, et al. Seroprevalence of pertussis toxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2009; 117: 912922.
33. Versteegh, FGA, et al. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis . Epidemiology and Infection 2005; 133: 737748.
34. Valdespino, JL, et al. Seroepidemiology of hepatitis A in Mexico. A detector of social inequity and monitor of immunization policies. Salud Publica de Mexico 2007; 49 (Suppl. 3): S377S385.
35. Healy, CM, Rench, MA, Baker, CJ. Implementation of cocooning against pertussis in a high-risk population. Clinical Infectious Diseases 2011; 52: 157162.
36. Castagnini, LA, et al. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clinical Infectious Diseases 2012; 54: 7884.
37. Skowronski, DM, et al. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clinical Infectious Diseases 2012; 54: 318327.
38. Munoz, F, Englund, J. Infant pertussis: Is cocooning the answer? Clinical Infectious Diseases 2011; 53: 893896.
39. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months – Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2011; 60: 14241426.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 5
Total number of PDF views: 58 *
Loading metrics...

Abstract views

Total abstract views: 354 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 17th August 2018. This data will be updated every 24 hours.